登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C29H53NO5
化学文摘社编号:
分子量:
495.73
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
奥利司他, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
SMILES string
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
InChI key
AHLBNYSZXLDEJQ-FWEHEUNISA-N
grade
pharmaceutical primary standard
API family
orlistat
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... LIPF(8513), PNLIP(5406)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。
Other Notes
溶液不完全澄清，小颗粒可能仍然悬浮。
Sales restrictions may apply.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
[Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].
Journal de pharmacie de Belgique, (2)(2), 67-68 (2009-09-11)
Peter Hertzman
PharmacoEconomics, 23(10), 1007-1020 (2005-10-21)
To calculate the cost effectiveness (from the Swedish healthcare perspective) of orlistat plus diet for an obese and overweight population in a 1-year weight-management responder programme versus a 1-year weight-management programme based on diet only. As a reference, orlistat plus
K Johansson et al.
Obesity reviews : an official journal of the International Association for the Study of Obesity, 11(11), 777-791 (2009-12-23)
Previous meta-analyses investigating blood pressure effects of anti-obesity drugs have included studies using non-licensed doses, but not data from head-to-head studies. Furthermore, although diabetes is an important comorbidity in obesity, variation in blood pressure effects across diabetes status has not
Monique P Curran et al.
Treatments in endocrinology, 4(2), 127-129 (2005-03-24)
Orlistat is an inhibitor of gastrointestinal lipases and, therefore, prevents the absorption of dietary fat. This agent reduced weight in obese adults and adolescents with or without co-morbidities (including type 2 diabetes mellitus, hypercholesterolemia, hypertension, metabolic syndrome) who received up
Miguel A Rubio et al.
Public health nutrition, 10(10A), 1200-1205 (2007-11-21)
Modification of lifestyle is the main therapeutical approach in the treatment of obesity, but use to fail on long terms of time. Addition of anti-obesity drugs allows keeping the weight loss during years and improving obesity-related comorbidities. This review is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持